Hematological Neoplasms

On May 15, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for an immunotherapy treatment for follicular lymphoma.

In recent years, CD19-targeted CAR-T cell therapy has achieved tremendous success in the field of B-cell non-Hodgkin’s lymphoma (B-NHL).

In October 18, 2017, the FDA approved Yescarta(Axicabtagene Ciloleucel), a CAR T-cell therapy, for the treatment of relapsed or refractory follicular lymphoma in adults after two or more prior lines of systemic therapy.

Lisocabtagene maraleucel (liso-cel) is an autologous CD19 4-1BB CAR-T cell product that has demonstrated high response rates and deep responses in treating R/R B-cell lymphomas.

However, the advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape for DLBCL, offering hope for improved outcomes and prolonged survival.

For relapsed/refractory (R/R) PCNSL, on the pathological level, the tumor cells are highly malignant and progress rapidly; on the patient level, the involvement of the brain is significant, leading to poorer function of other organs, and neurological function and physical condition often deteriorate rapidly.

The American Journal of Hematology and Hemasphere recently published articles investigating the application of CAR-T in elderly DLBCL patients, one comparing CAR-T with immunochemotherapy in the elderly subgroup, and the other comparing CAR-T treatment in patients <70 years and ≥70 years.

The editor has selected an “Oral Presentation” (S240)[2] to provide insights into the efficacy and toxicity of anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed or refractory primary mediastinal B-cell lymphoma (R/R PMBL), and to investigate factors associated with treatment outcomes.

June 22nd is designated as CAR-T Day, to commemorate the official approval and launch of Axicabtagene Ciloleucel in China, marking the beginning of the CAR-T cell therapy era in China.

The National Cancer Institute (NCI) in the United States first reported successful cases of second-generation CD19 CAR-T cell therapy.

Recently, the Department of Hematology at the University Hospital of Rennes in France published a journal review titled “Remission After CAR-T Cell Therapy: Can Lymphoma Patients Return to a Normal Life?” in the medical journal HemaSphere.

Although immunochemotherapy is initially effective, its efficacy gradually diminishes, and toxicity may accumulate.